Citrin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Citrin

What is Citrin? (Overview)

Property Description
Active ingredient Cetirizine Hydrochloride
Form Film-coated tablets, Oral solution, Syrup
Pharmacological class Second-generation H₁ receptor antagonist
General purpose Mitigating symptoms of allergic conditions
Origin Synthetic (Carboxylic acid derivative)

Identity and Pharmacological Classification

Citrin is a medicinal entity defined by its single active component, Cetirizine Hydrochloride, and is classified as a synthetic antihistamine belonging to the second generation of H₁ receptor antagonists. This classification signifies that the compound is chemically synthesized and engineered for systemic action to target specific receptors in the body. Its structural identity as a Carboxylic acid derivative supports its highly selective action profile. Clinical data supports that this medicine helps reduce the body's reaction to allergens by blocking the effects of a key inflammatory chemical.

Composition, Forms, and General Purpose

The compound is supplied as a single product (monotherapy) and is taken via the oral route, achieving systemic action to treat allergic processes throughout the body. Citrin is typically formulated for patient use in various dosage forms, including film-coated tablets, oral solution, and syrup, which may include specific flavorings for administration. As a compound of this class, it exerts its effect by specifically blocking peripheral receptors. This functions to mitigate uncomfortable manifestations like seasonal allergic rhinitis or chronic urticaria, offering general relief from hypersensitivity reactions.

High-Level Mechanism Principle

The core principle of this class involves the selective antagonism of peripheral H₁-receptors. This means Cetirizine works by competitively binding to receptor sites outside the central nervous system, effectively preventing the inflammatory chemical histamine from triggering allergic responses. This second-generation antihistamine characteristic is vital: its low-to-minimal penetration of the blood-brain barrier (BBB) means the drug is designed to provide systemic relief while largely avoiding interaction with central nervous system functions, which is a recognized advantage supporting its use when minimal impact on cognitive function is desired.

Regulatory References

  1. NIH StatPearls: Cetirizine

What side effects are possible with Citrin?

Possible Side Effects and Safety Information for Citrin

Note on Regulatory Status:

Citrin is not currently recognized as a pharmaceutical active substance with an official, documented safety profile in major global governmental regulatory databases (such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Health Canada, or others).

Regulatory bodies require official drug labels (Prescribing Information or Summary of Product Characteristics) to comprehensively detail all known side effects (adverse reactions), categorized by frequency and seriousness. Because Citrin lacks this formal regulatory recognition, no official, state-verified safety profile is available for this substance.


Official Regulatory Safety Structure

The table below summarizes the information that would typically be present in a government-approved drug label, which is currently unavailable for Citrin:

Safety Element Status in Official Regulatory Documents
Frequency-Classified Adverse Reactions Not available (No official list by frequency is documented.)
System-Organ-Class Groupings Not available (No official grouping by body system is documented.)
Serious Adverse Reactions Not available (No specific serious risks are officially defined.)
Population-Specific Safety Notes Not applicable (No official safety data for specific populations is documented.)
Safety-Related Restrictions Not available (No official restrictions or limitations are documented.)

Regulatory Safety Summary:

The absence of official labeling means there are no officially documented categories of adverse reactions or defined serious risks. A formal, government-verified safety framework—which is essential for understanding the medicine's risk profile—is not established for Citrin.

Overdose and Emergency Response

Overdose and When to Seek Help

The information below summarizes the overdose profile of Citrin (Cetirizine Hydrochloride) as documented in official government regulatory sources, detailing documented clinical effects and mandated emergency actions.


Documented Clinical Manifestations

Official labeling records a spectrum of symptoms following an overdose. Commonly reported manifestations involve the central nervous system, including drowsiness and somnolence. More severe, though less frequent, outcomes recorded in regulatory documents include convulsions, syncope (fainting), coma, tachycardia (rapid heart rate), tremor, and confusion. In infants, initial restlessness and irritability have been specifically documented.


Required Emergency Action and Management

Immediate medical attention is mandatory upon known or suspected overdose. The U.S. FDA prescribing information explicitly states: "In case of overdose, get medical help or contact a Poison Control Center right away."

Management: There is no known specific antidote for Citrin overdose. Treatment, as described by regulators, focuses entirely on symptomatic and supportive care. Procedures such as gastric lavage or the administration of activated charcoal may be considered by medical professionals shortly after a massive ingestion.

Population Note: Regulatory documents highlight that patients with renal impairment (kidney disease) are at increased risk for adverse effects from overdose due to slower drug clearance.

Therapeutic Uses of Citrin

What Citrin Treats: Main Uses and Benefits

Treatment related to Citrin deficiency is applied across domains where additional symptomatic support is needed, managing symptoms that interfere with daily functioning, often related to metabolic or systemic imbalance. It is observed that this condition may present with delayed growth and extreme tiredness. The treatment provides support that helps ease the overall symptom burden and assists with maintaining functional stability.

This support is commonly used to help with symptom clusters that may become intense or disruptive, such as chronic fatigue, challenges with growth, discomfort related to liver function, and acute episodes of confusion or lethargy. This assistance may help patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.


Quick Facts

  • Symptom Management Focus: Supportive management is relevant when symptoms, such as confusion, become temporarily overwhelming, helping to ease distress during acute episodes.
  • Scope: Used in situations involving certain distressing symptoms related to systemic imbalance and liver stress, offering short-term symptom management.

Regulatory References

  1. NIH MedlinePlus Genetics

Eligibility and Restrictions for Use

Official Eligibility Profile

This section describes the populations formally included and excluded from using the medicine based strictly on regulatory documents, such as the EMA Summary of Product Characteristics and FDA Prescribing Information.

Populations Excluded from Use

Classification Population Regulatory Basis
Use Not Established Patients with CITRIN (citrullinaemia type 2) deficiency Safety and efficacy have not been formally established by regulatory authorities for this specific patient group, resulting in exclusion from the approved indications.
Contraindicated Individuals with known hypersensitivity to the active substance (phenylbutyrate) or any other components. Prohibition of use due to risk of severe allergic reaction.
Use Not Established Infants younger than two months of age Lack of sufficient data to establish safety and effectiveness in this age group.

Conditional or Restricted Use

Restriction Type Population Condition
Caution Required Patients with severe renal impairment or hepatic impairment Use requires special consideration, often involving reduced starting doses, due to potential impairment of drug clearance.
Adjunctive Therapy All eligible patients The medicine must be used in conjunction with a strict protein-restricted diet and, in some cases, necessary dietary supplements.

The regulatory documentation clearly defines who must not use the medicine by classifying certain groups based on either a lack of established efficacy data (e.g., CITRIN deficiency patients) or a recognized health risk (e.g., hypersensitivity). Use is also restricted based on age and organ function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section addresses formally documented interaction patterns for Citrin (Cetirizine Hydrochloride) based strictly on government regulatory information, describing explicit constraints and classifications.

Official Interaction Categories

Interaction Type Interacting Substances/Conditions Official Outcome Description
Pharmacodynamic Alcohol and CNS Depressants (e.g., Sedatives) Co-administration carries the risk of additive reductions in alertness and potential further impairment of central nervous system performance.
Pharmacokinetic Theophylline (400 mg once daily) Official studies document that this co-administration results in a 16% decrease in the clearance of Cetirizine, leading to increased systemic exposure.
Contraindication Hydroxyzine and Piperazine derivatives Use is formally contraindicated in patients with known hypersensitivity to the medicine or these structurally related compounds.
No Significant Interaction Food, Azithromycin, Erythromycin No clinically significant interaction affecting Cetirizine absorption or disposition is documented with food or co-administered with these specific medicines.

Population-Specific Considerations

The systemic disposition of the medicine is formally noted to be altered in certain populations. Individuals with Chronic Liver Disease or established Renal Impairment exhibit a documented reduced clearance and a prolonged elimination half-life of Cetirizine, which increases systemic exposure.

Context Summary

Regulatory documents define the product's interaction structure through mandatory restrictions based on chemical cross-sensitivity and pharmacodynamic warnings concerning the potential for additive CNS effects. This official profile also includes specific pharmacokinetic findings detailing altered clearance when co-administered with Theophylline, while confirming the absence of clinically significant interactions with several common antibiotic and antifungal agents.

Mechanism of Action

The action of Citrin (Cetirizine Hydrochloride) is defined by its selective influence on histamine signaling mechanisms.

️ Selective Blockade of Peripheral H₁ Receptors

The primary mechanism involves competitive antagonism at the peripheral Histamine mathbfH1 receptors. This molecular interference physically blocks the inflammatory mediator histamine from binding to and activating these receptors, which are crucial components of the early immune response cascade. This precise targeting contributes to reducing activity within the signaling pathway that initiates increased vascular permeability and sensory nerve activation.

Modulation of Vascular and Cellular Pathways

Beyond direct receptor blockade, the drug modulates two crucial physiological processes: it decreases vascular permeability by inhibiting histamine's effect on blood vessel walls, and it exhibits a secondary inhibitory influence on the late-phase recruitment of inflammatory cells, such as eosinophils. These combined actions alter the systemic physiological consequence by decreasing fluid accumulation in tissues and modulating the late-phase recruitment of inflammatory cells, contributing to a reduced level of pathway activation within affected areas.

Dosage and Administration Information

The usage of Citrin (Cetirizine Hydrochloride) is governed by established parameters that determine its administration route, dosing, and schedule. The drug is primarily taken via the oral route as a film-coated tablet, capsule, or oral solution. For specific acute settings, an intravenous (IV) injection is available and is administered as an IV push over a defined 1- to 2-minute interval in a supervised context.

The standardized adult dosing regimen is 10 mg taken once daily. For those with less severe symptoms, a starting dose of 5 mg once daily may be used. The drug may be taken with or without food, and tablets are typically swallowed whole with liquid. The medication maintains a consistent once-daily frequency (every 24 hours) for both short-term, as-needed use and longer-term, seasonal use.

A critical requirement is the dose reduction for patients with impaired renal function. For individuals with moderate impairment, the dose is typically reduced to 5 mg once daily; those with severe impairment may require dosing as infrequently as 5 mg once every two days. In some regions, a 5 mg twice daily schedule is specified for children aged 6 to 12 years. Administration of the oral solution involves a calibrated measuring device to ensure accuracy, and the tablet form is generally not recommended for children under 6 years due to necessary dose flexibility.

Recent Clinical Evidence

Research evidence / Overview of studies for Citrin

The evidence for Citrin (Cetirizine Hydrochloride) is primarily derived from clinical investigations designed as Randomized Controlled Trials (RCTs), systematic reviews, and comparative studies. This research base is applied in studies examining patient-reported experiences related to symptoms. The evidence highlights what is known—and what is still uncertain. Findings describe group patterns, and research provides context but not individual predictions.


Evidence for Use in Allergic Rhinitis (Seasonal and Perennial)

Research exploring short-term symptom patterns in allergic rhinitis was applied in studies examining patient-reported experiences related to outcomes linked to inflammatory or irritative states. Researchers sought to measure changes in Total Nasal Symptom Score (TNSS), a metric used in research examining symptom intensity or variability. The findings describe patterns observed in the studies related to outcomes related to physical discomfort, and research describes how symptoms evolved in the observed populations when comparing the medicine to a placebo or other active agents. What remains uncertain is the need for more recent, large-scale comparative evidence and that long-term effects are not fully established for continuous use.

Evidence for Use in Chronic Urticaria (Chronic Hives)

For chronic urticaria, research was used in studies examining outcomes related to physical discomfort, specifically tracking the severity of pruritus (itching) and the physical characteristics of wheals (hives). The data show patterns related to the observed changes in wheals and itching compared to a control group. Research describes evaluation of non-standard doses, which was observed in some studies, but evidence quality varies across studies and findings were mixed. Long-term effects are not fully established for this condition, as follow-up durations were limited in many studies.

Evidence in Special Populations

The evidence landscape includes research exploring short-term symptom changes for subgroups defined by age or co-occurring conditions. Research was studied for outcomes monitoring physiological strain or stress in pediatric populations, with studies including infants as young as 6 months. Data for certain groups remain insufficient; specifically, studies did not include enough patients aged 65 years and older to fully explore potential different patterns.

Key Studies & References

  1. Cetirizine: StatPearls - NCBI Bookshelf (Updated information on efficacy and populations)
  2. Cetirizine for the treatment of allergic diseases in children: a systematic review (Evidence base for pediatric populations)

Frequently Asked Questions (FAQ)

Common questions about Citrin (FAQ)


Q: Can Citrin be taken indefinitely, or is it intended for short-term use?

Studies and official information indicate that for long-term conditions like chronic urticaria (hives), continuous daily use of the active ingredient in Citrin is a pattern described in clinical guidelines for management. However, there have been some reports of rebound itching (pruritus) when the medication is stopped, especially after extended use.


Q: Can older adults safely use Citrin according to official guidance?

Regulatory documents state that a dose reduction is generally not necessary for older adults whose kidney function is within the normal range. However, individuals with any degree of impaired renal function (kidney issues) necessitates a dose adjustment, as described in regulatory documents.


Q: Are there any known dietary restrictions when taking Citrin?

Official product information states that no specific food restrictions are required when taking this medication. Citrin may be taken with or without food, as food does not significantly affect the total amount of the drug absorbed into the body.


Q: How quickly does Citrin leave the system after stopping treatment?

The elimination half-life of the active ingredient in adults averages about 8.3 hours. After the last dose, it takes several half-lives for the medicine to be fully cleared from the body.


Q: Does Citrin affect concentration or ability to drive?

Official documents caution that Citrin may cause side effects like drowsiness, dizziness, or reduced alertness in some patients. Official warnings advise caution regarding activities like driving or operating machinery, as the medicine may cause drowsiness or reduced alertness.


Q: Does alcohol consumption interfere with Citrin's effectiveness?

Regulatory documents primarily focus on the safety profile, noting that the combination may cause an additive reduction in alertness and potential further impairment of central nervous system performance, leading to official warnings against co-administration.


Q: Do official documents mention a maximum recommended treatment duration for Citrin?

Official documents do not define a specific maximum treatment duration. For chronic allergic conditions, long-term or continuous use may be recommended. The necessity for and duration of continuous use is a matter for individual clinical determination.


Q: Does the efficacy of Citrin depend on the patient's age?

Official dosing instructions vary by age group, with specific regimens recommended for children. However, for older adults, efficacy is generally maintained, and no dose reduction is typically needed if their kidney function is normal.


Q: Do official prescribing documents contain warnings about operating heavy machinery while using Citrin?

Yes, official documents contain warnings that, due to the potential for sedation (sleepiness) and reduced alertness, caution is advised when operating potentially hazardous machinery. This guidance is in place until the user is familiar with their individual response to the medication.


Q: Can environmental factors, like extreme heat, affect Citrin's safety or efficacy?

Regulatory labeling mandates specific storage conditions, requiring the medicine to be kept at a controlled room temperature (typically 20 C to 25 C). Exceeding these temperatures could potentially affect the medication's stability and, consequently, its efficacy and safety.


Q: Does Citrin cause weight gain or weight loss?

Regulatory safety information indicates that weight increase has been reported as an adverse reaction in a small percentage of patients (0.4%) during clinical trials.


Q: How long does it usually take to feel the effects of Citrin?

The onset of action for symptomatic relief is typically rapid, with effects often seen within 20 to 60 minutes after taking an oral dose.


Q: Does Citrin affect sleep patterns or cause insomnia?

While Citrin can cause drowsiness in some people, insomnia (trouble sleeping) has also been reported as an uncommon psychiatric side effect in post-marketing experience reports.


Q: Why do some people experience initial nausea when starting Citrin?

Nausea is listed in regulatory documents as an uncommon gastrointestinal side effect. This information is documented in the full safety profile.


Q: Can Citrin interact with common over-the-counter pain relievers?

Official warnings primarily focus on the additive risk of sleepiness when Citrin is taken with opioid pain relievers, which are central nervous system (CNS) depressants. Determining the safety profile with other over-the-counter pain relievers requires individual review by a clinician.


Q: Is it normal to feel tired or fatigued after starting Citrin?

Yes, fatigue (tiredness) and somnolence (drowsiness) are listed as common adverse reactions in the regulatory safety profile for Citrin.


Q: What does official guidance say about using Citrin during pregnancy?

Regulatory guidance states that use during pregnancy is advised only if the benefit justifies the potential risk to the fetus. The use of this medicine during pregnancy or planning for it requires clinical review.


Q: Are headaches a commonly reported side effect of Citrin?

Yes, headache is listed as a common adverse reaction in the regulatory safety profile for this medicine.


Q: Is it possible to develop a tolerance to Citrin over time?

Clinical studies have shown that tolerance to the antihistaminic effect, such as the suppression of wheals and flares, does not develop even after one month of daily treatment at the recommended dose.


Q: Is it safe to use herbal teas or remedies while taking Citrin?

Regulatory documents note that caution is generally necessary when using other medications or supplements, particularly those that may also cause drowsiness. The combination of such products with Citrin may lead to an increased risk of sedation.


Q: Why do patients sometimes experience mild dizziness on Citrin?

Dizziness is listed in the official safety documents as a common adverse reaction associated with taking Citrin.


Q: What is the risk of withdrawal symptoms if Citrin is stopped suddenly?

The sudden onset of severe itching (rebound pruritus) or hives has been reported when the medicine is stopped, particularly after long-term, continuous use.


Q: Are there any known interactions between Citrin and common anesthetic agents?

Official warnings include cautions regarding co-administration with any Central Nervous System (CNS) depressants, which include some anesthetic agents. The risk of additive reductions in alertness and impairment is the basis for this caution.


Q: What should a patient do if they accidentally take a double dose of Citrin?

Regulatory information lists symptoms that may occur during overdose, such as extreme sleepiness, changes in mood, and irritability. Official guidance directs seeking immediate assistance from a healthcare provider or a local Poison Control Center if an overdose is suspected.


Q: Is Citrin known to cause any skin reactions or rashes?

Regulatory documents list pruritus (itching) and rash as uncommon side effects. Severe skin reactions have been reported very rarely.


Q: Are there any official reports of Citrin causing mood changes or irritability?

Yes, irritability, depression, confusion, and hallucinations are listed as rare psychiatric adverse reactions in the official safety information.


Q: Can Citrin affect fertility or reproductive hormones?

Adverse reactions related to reproductive health, such as decreased libido (sex drive), menstrual disorder, and erectile dysfunction, have been reported very rarely in official safety documents.


Q: What is the purpose of the inactive ingredients listed in Citrin tablets?

Inactive ingredients (known as excipients) are listed in official documents and serve functions such as forming the tablet or ensuring its stability. Regulatory guidance emphasizes that patients with known sensitivities to components like lactose or specific preservatives must review the full ingredient list.


Q: Is it true that Citrin needs to be tapered off rather than stopped abruptly?

The sudden onset of severe itching has been reported when the medicine is stopped, particularly after long-term use. The potential for this rebound effect indicates that discontinuation should be discussed with a healthcare provider.

How should Citrin be stored and disposed of?

Storage and Disposal Conditions

Official regulatory labeling dictates specific conditions for storing and disposing of cetirizine products (Citrin) to maintain quality and safety.


Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Do not store above 30 C for some liquid formulations.
Protection Keep the medicine out of the reach of children. Do not use if the original container's foil seal or blister unit is broken or compromised.
Stability Specific liquid preparations that are mixed may have a limited stability period, such as two hours at room temperature, or up to 24 hours if refrigerated.

Disposal

Unused or expired product must be disposed of in accordance with local requirements. Consumers are directed to utilize drug take-back programs when available, or to follow local procedures for discarding non-hazardous medicinal waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Citrin found in:

A-Z Index: